A number of reports pointed out that the development of colitis‐associated colon disease models is related to multiple factors from both canonical NF‐κB and noncanonical NF‐κB pathway.13, 27 To evaluate the role of TRIM14 in NF‐κB signaling in vivo, we applied the inflammation‐driven colitis‐associated cancer (CAC) model28 by intraperitoneal subjecting mice with an azoxymethane (AOM) and disuccinimidyl suberate (DSS) treatment together, which could stimulate the colon tumorigenesis (Figure S2A, Supporting Information). Here, TRIM14 is linked to colonic disorder.